Phase III trial of Blenrep misses goal in multiple myeloma

UK pharma major GSK’s (LSE: GSK) shares were down 4.3% at 1,383.60 pence by early afternoon today, as it announced disappointing Phase III results with its Blenrep (belantamab mafodotin).

The company revealed that Blenrep monotherapy versus pomalidomide in combination with low dose dexamethasone (PomDex) in patients with relapsed or refractory multiple myeloma (RRMM) did not meet its primary endpoint of progression-free survival (PFS), denting hopes the company can move it up to earlier lines of treatment.

Data from the so-called superiority trial dubbed DREAMM-3 may call into question Blenrep's existing approval, according to JP Morgan analysts, who noted that many regulatory scenarios now exist, including existing approvals being rescinded or authorities waiting for further data.